Literature DB >> 28760835

Public drug policy for children in Canada.

Avram E Denburg1, Wendy J Ungar2, Mark Greenberg2.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28760835      PMCID: PMC5536988          DOI: 10.1503/cmaj.170380

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  16 in total

1.  Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice.

Authors:  Julia Abelson; Mita Giacomini; Pascale Lehoux; Francois-Pierre Gauvin
Journal:  Health Policy       Date:  2006-09-22       Impact factor: 2.980

Review 2.  Priority setting for health technology assessments: a systematic review of current practical approaches.

Authors:  Hussein Z Noorani; Donald R Husereau; Rhonda Boudreau; Becky Skidmore
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

3.  Values and evidence colliding: health technology assessment in child health.

Authors:  Wendy J Ungar; Lisa A Prosser; Heather F Burnett
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2013-08       Impact factor: 2.217

Review 4.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 5.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

Review 6.  Alternative designs for clinical trials in rare diseases.

Authors:  Lusine Abrahamyan; Brian M Feldman; George Tomlinson; Marie E Faughnan; Sindhu R Johnson; Ivan R Diamond; Samir Gupta
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-14       Impact factor: 3.908

7.  The significance of age and duration of effect in social evaluation of health care.

Authors:  E Nord; A Street; J Richardson; H Kuhse; P Singer
Journal:  Health Care Anal       Date:  1996-05

Review 8.  The economics of pediatric formulation development for off-patent drugs.

Authors:  Christopher-Paul Milne; Jon B Bruss
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

9.  Drug research and treatment for children in Canada: A challenge.

Authors:  Michael J Rieder
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

10.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655

View more
  4 in total

1.  Pediatric drug data in Canadian drug monographs: a descriptive analysis.

Authors:  Preeya Raja; Mark Duffett; Maryann Mazer-Amirshahi; Ashaka Patel; Andrea Gilpin; Catherine Litalien; Anthony K Chan; John van den Anker; Thierry Lacaze-Masmonteil; Samira Samiee-Zafarghandy
Journal:  CMAJ Open       Date:  2020-08-31

2.  The Moral Foundations of Child Health and Social Policies: A Critical Interpretive Synthesis.

Authors:  Avram E Denburg; Mita Giacomini; Wendy J Ungar; Julia Abelson
Journal:  Children (Basel)       Date:  2021-01-13

3.  Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy.

Authors:  Avram E Denburg; Mita Giacomini; Wendy Ungar; Julia Abelson
Journal:  Int J Health Policy Manag       Date:  2022-03-01

4.  'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.

Authors:  Avram E Denburg; Mita Giacomini; Wendy J Ungar; Julia Abelson
Journal:  Int J Equity Health       Date:  2020-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.